跳至主要内容
临床试验/EUCTR2011-000633-36-ES
EUCTR2011-000633-36-ES进行中(未招募)1 期

A randomised, controlled, assessor-blind, parallel groups, multinational,multicentre trial assessing the dose-response relationship of FE 999049in controlled ovarian stimulation in women undergoing an assistedreproductive technology programme

Ferring Pharmaceuticals A/S0 个研究点目标入组 330 人开始时间: 2011年8月9日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
330

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • Women diagnosed with tubal infertility, unexplained infertility, infertility related to endometriosis stage I/II or with partners diagnosed with male factor infertility, eligible for IVF and/or ICSI treatment will be included in this trial. Subjects will be 18-37 years of age, with a body mass index (BMI) of 18.5-32.0 kg/m2 and have serum AMH levels within 5.0-44.9 pmol/L at the screening visit based on the central laboratory analysis.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 330
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Women with polycystic ovary syndrome (PCOS) associated with anovulation, endometriosis stage III/IV, history of recurrent miscarriage or with contraindications to controlled ovarian stimulation with gonadotropins will be excluded from participation in this trial. Women with three or more controlled ovarian stimulation cycles will also be excluded.

研究者

相似试验

进行中(未招募)
1 期
MENOPUR and REKOVELLE in Women UnderGoing an assisted reproductive technology cycleInfertility in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle
CTIS2022-500308-23-00Ferring Pharmaceuticals A/S151
进行中(未招募)
1 期
A randomised, controlled, assessor-blind, parallel groups, multicentre, multinational trial comparing the efficacy and safety of FE 999049 with follitropin alfa (GONAL-F) in controlled ovarian stimulation in women undergoing an assisted reproductive technology programmeInfertility
EUCTR2013-001669-17-PLFerring Pharmaceuticals A/S1,350
进行中(未招募)
不适用
A randomised, controlled, assessor-blind, parallel groups, multinational,multicentre trial assessing the dose-response relationship of FE 999049in controlled ovarian stimulation in women undergoing an assistedreproductive technology programmeMedDRA version: 14.0Level: PTClassification code 10021926Term: InfertilitySystem Organ Class: 10038604 - Reproductive system and breast disordersInfertility
EUCTR2011-000633-36-DKFerring Pharmaceuticals A/S330
进行中(未招募)
1 期
A randomised, controlled, assessor-blind, parallel groups, multicentre, multinational trial comparing the efficacy and safety of FE 999049 with follitropin alfa (GONAL-F) in controlled ovarian stimulation in women undergoing an assisted reproductive technology programmeMedDRA version: 14.1Level: PTClassification code 10021926Term: InfertilitySystem Organ Class: 10038604 - Reproductive system and breast disordersInfertility
EUCTR2013-001669-17-ESFerring Pharmaceuticals A/S1,350
进行中(未招募)
1 期
A randomised, controlled, assessor-blind, parallel groups, multicentre, multinational trial comparing the efficacy and safety of FE 999049 with follitropin alfa (GONAL-F) in controlled ovarian stimulation in women undergoing an assisted reproductive technology programmeMedDRA version: 14.1Level: PTClassification code 10021926Term: InfertilitySystem Organ Class: 10038604 - Reproductive system and breast disordersInfertility
EUCTR2013-001669-17-GBFerring Pharmaceuticals A/S1,350